Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553366 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2HIF1ATAAR1ALDH1A1HTR1A | |
| SCHEMBL17129221 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1SYKNPC1RAB9A | |
| SCHEMBL30257063 | 0.87 | AAK1 (0.47) | SMN1; SMN2SYKCTSSCTSKNPC1 | |
| SCHEMBL16363856 | 0.87 | CTSS (0.45) | SMN1; SMN2SYKCTSSCTSKNPC1 | |
| SCHEMBL29861722 | 0.87 | NPC1 (0.43) | SMN1; SMN2SYKNPC1RAB9ALMNA | |
| SCHEMBL24298740 | 0.87 | NPC1 (0.43) | SMN1; SMN2SYKCTSSCTSKNPC1 | |
| SCHEMBL2434610 | 0.87 | CTSS (0.45) | SMN1; SMN2SYKCTSSCTSKNPC1 | |
| SCHEMBL17373694 | 0.87 | AAK1 (0.47) | SMN1; SMN2SYKCTSSCTSKNPC1 | |
| SCHEMBL3657534 | 0.87 | GAA (0.48) | SMN1; SMN2ALDH1A1SYKNPC1RAB9A | |
| SCHEMBL29861985 | 0.87 | NPC1 (0.43) | SMN1; SMN2SYKNPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023126978-A1 | PROCESS TO PREPARE OCTOPAMINE SULFATE | DIRECTOR, NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH, GUWAHATI (NIPER-G) (IN) | 2023-07-06 | — | — | WO | disclosed |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| WO-2011105572-A1 | NOVEL HETEROARYL DERIVATIVE | 持田製薬株式会社 (JP) | 2011-09-01 | — | — | WO | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| EP-1778653-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7192722-B2 | Phenethanolamine-derived haptens, immunogens, antibodies and conjugates | RANDOX LABORATORIES (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006022794-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | SMN1; SMN2 4690/4885HIF1A 3365/4885TAAR1 1883/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | SMN1; SMN2 4690/4885HIF1A 3365/4885TAAR1 1883/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | SMN1; SMN2 2927/4885HIF1A 2956/4885TAAR1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.